Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Hematological Parameters Extended for Automated Analyzer

By LabMedica International staff writers
Posted on 20 Jul 2011
The quantification of the percentages of microcytic and hypochromic erythrocytes has proved clinically useful in the differential diagnosis of anemia. More...


Based on classical hematological parameters, subjects with iron deficiency anemia (IDA) are inappropriately differentiated from subjects with anemia owing to thalassemia or chronic disease.

A study conducted at the Hospital Galdakao-Usansolo, (Galdakao, Spain), aimed to establish characteristic analytical features, including the new erythrocyte and reticulocyte parameters, in case of thalassemia trait and IDA. The study population included 90 healthy individuals, 136 β-thalassemia carriers, 121 with mild IDA, and 126 with severe IDA. The scientists used the Sysmex XE 5000, which utilizes the flow fluorescence-cytometry technology, enables independent measurement of the volume and hemoglobin (Hb) content of individual red cells (RBC). Derived from this technology, four new RBCs extended parameters, erythrocyte subsets, are now reported for this analyzer.

When using the Sysmex XE 5000 analyzer, (Sysmex Corporation, Kobe, Japan; www.sysmex.com), the percentages of erythrocyte subsets can be calculated and the new parameters, such percentage of microcytic red cells (%Micro R) and percentage of macrocytic red cells (%Macro R) can be obtained. In the reticulocyte channel, blood cells are stained by a polymethine dye specific for ribonucleic acid, (RNA) /DNA, and analyzed by flow cytometry using a semiconductor laser. A bidimensional distribution of forward scattered light and fluorescence is presented as a scattergram, indicating mature red cells and reticulocytes. Forward scatter correlates with reticulocyte hemoglobin content (Ret He) and erythrocyte hemoglobin content (RBC He).

The results of the study indicate that although the differences between the three groups of anemic patients were statistically significant, the central 95th percentile ranges showed considerable overlap for most hematological parameters including absolute reticulocyte count. The values obtained for the RBC extended parameters were significantly different in the groups. The %Micro R was more increased in thalassemia (38.6 %) than in the mild IDA (16.5%), and in severe IDA (21.6%). Immature reticulocyte fraction (IRF) mean values in the groups were statistically different as the thalassemia group had an intermediate value of 8.7%, which was between the healthy value of 4.4% and IDA values ranging from 12.9% to 16.7%.

The authors concluded the erythrocytosis and severe microcytosis, together with a high percentage of microcytes and a moderate increase in IRF, is the profile of β-thalassemia carriers, whereas anisocytosis and the hypochromic subset correlates with the severity of the anemia in iron-deficient patients. The study was published online on May 12, 2011, in Journal of Clinical Laboratory Analysis.

Related Links:

Hospital Galdakao-Usansolo
Sysmex Corporation



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.